Search Results

CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session V Structural mechanisms of AGPCR signaling and function Structural Determinants Of GAIN Domain Autoproteolysis And Cleavage Resistance Of Adhesion G Protein-Coupled Receptors Fabian Pohl Structural studies of the CELSR1 We de-termined the crystal structure of the human ADGRB2/BAI2 hormone receptor (HormR) and GAIN domains unique structural features that are important for autoproteolytic cleavage, beyond the canonical HXS

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation

New cryo-EM structures from Chen et al. New cryo-EM structures from Chen et al.

With a deep focus on structure-based drug design, Jens discusses how his lab bridges simulation and experiment—and From virtual screening of billions of molecules to leveraging AlphaFold for structure prediction, Jens You’ll Learn Why Jens Carlsson believes modeling should predict , not just explain How his team uses structure-based collaborations between modelers and experimentalists are more vital than ever How AlphaFold is shaking up structural a research career Who Should Listen GPCR scientists and pharmacologists Computational chemists and structural

Home → Flash News → ep 175 with jens carlsson clip 3 AI is changing how we think about structure, function GPCR Podcast AI is changing how we think about structure, function, and discovery — but Jens Carlsson A good model doesn’t just match published structures; it forecasts new biology, new ligands, and new

Schwartz, and worked closely with Dr Birgitte Holst studying structural and mechanistic properties of Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

He earned his PhD in Physics at the same university, focusing on in silico structural vaccinology and Now in a tenure-track position, his research spans the development of computational methods such as structure-based Scholar ResearchGate Bysky App : @ riccardocapelli.bsky.social Twitter X : @ ric_capelli Computational Structural

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic

A landmark Cell paper delivers the answer—mapping how conserved and variable sequence–structure elements “private” binding determinants ♦️ Highlights role of structured + unstructured regions ♦️ Includes a

signaling mechanisms employed by these atypical 7-transmembrane receptors, combining biochemical and structural begun studying GPCR signaling pathways that operate within the primary cilium, a tiny antenna-shaped structure Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure

Ray Stevens in 2013 solving several GPCR crystal structures, including that of the first serotonin receptor Bryan Roth where I established GPCR structural biology and learned the ins and outs of molecular pharmacology started my own lab at the Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke the AudetLab located at the Institute of Pharmacology of Sherbrooke and is an emerging leader in the structural

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural

Communications, which she joined in April 2020, following three years on the editorial teams of Nature Structural Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus

With hundreds of subtypes and very few known ligands, the structure–function relationships remain largely .” – Alessandro Nicoli He explained how AlphaFold’s predictions, surprisingly close to experimental structures More structures, better tools, and deeper insights into the elegant, complex world of GPCRs. By bridging structural prediction, molecular dynamics, and ligand discovery, his work not only deciphers Alessandro PhD work aims to fill these gaps by leveraging computational structure-based tools and develop

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic

Current affiliation: Department of Structural Biology, Genentech, South San Francisco, CA, USA" About Kordon "I am a postdoctoral scholar in the Araç Lab at The University of Chicago, studying the structure Utilizing synthetic antibody fragments, I aim to understand better the structural basis of the aGPCRs University of Copenhagen, Copenhagen, Denmark. (2) Department of Psychiatry and Molecular Pharmacology and Therapeutics Columbia University Vagelos College of Physicians and Surgeons, New York, USA; Division of Molecular Therapeutics

I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. of California in San Francisco to continue his training as a postdoctoral researcher where he used structural

But in the quiet hours, he found himself drawn to the structures, to the models, to figuring out why Today, Jens is a Professor of Computational Biochemistry at Uppsala University , where his lab uses structure-based

His Ph.D. work has been focused on understanding the structure and activation of Class D fungal GPCRs developed novel tools and methodologies to study fungal GPCRs which allowed the determination of the first structures

The overall goal of her research program is to obtain rigorous mechanistic insights into the structure To this end, her lab uses several computational structural biology tools and rational drug design approaches

Presentations Health and Disease, Metabolism, Nervous System, Proteomics and Transcriptomics, Receptor Structure The shorter BAI1 isoforms lack most of the N-terminus and are very close in structure to the truncated graduate student, he worked in the EuGEF Research Group to identify novel prognostic biomarkers and therapeutic significant tissue-specific mRNA processing that results in holoreceptors with unique and variable N-terminal structures Clearly, a new, less toxic therapeutic is needed.

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics